Publication of trial of EVK 001 for Diabetic Gastroparesis

Evoke Pharma has announced the publication of a study that found intranasal delivery of EVK 001 (metoclopramide) to be more effective in managing symptoms of Diabetic Gastroparesis compared to the marketed oral tablet formulation of metoclopramide. The Phase IIb study, which was published online ahead-of-print for an upcoming issue of Neurogastroenterology & Motility, enrolled 89 patients from six study sites throughout the United States. The multicenter, randomized, open-label, parallel design study was the first to compare the efficacy and safety of metoclopramide nasal spray to oral tablets in diabetic patients with symptoms of Gastroparesis when dosed four times a day for 6 weeks.

See-"Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet,"-H. P. Parkman, M. R. Carlson and D. Gonyer- Neurogastroenterology & Motility, Article first published online: 25 DEC 2013 | DOI: 10.1111/nmo.12296.